- Home
- CUBA vs VYNE Comparison
CUBA vs VYNE Comparison
Compare CUBA & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBA
- VYNE
- Stock Information
- Founded
- CUBA 1992
- VYNE 2003
- Country
- CUBA United States
- VYNE United States
- Employees
- CUBA N/A
- VYNE N/A
- Industry
- CUBA Investment Managers
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- CUBA Finance
- VYNE Health Care
- Exchange
- CUBA Nasdaq
- VYNE Nasdaq
- Market Cap
- CUBA 38.4M
- VYNE 41.9M
- IPO Year
- CUBA N/A
- VYNE 2018
- Fundamental
- Price
- CUBA $2.42
- VYNE $2.98
- Analyst Decision
- CUBA
- VYNE Strong Buy
- Analyst Count
- CUBA 0
- VYNE 2
- Target Price
- CUBA N/A
- VYNE $6.88
- AVG Volume (30 Days)
- CUBA 93.9K
- VYNE 122.3K
- Earning Date
- CUBA 01-01-0001
- VYNE 11-07-2024
- Dividend Yield
- CUBA 20.83%
- VYNE N/A
- EPS Growth
- CUBA N/A
- VYNE N/A
- EPS
- CUBA N/A
- VYNE N/A
- Revenue
- CUBA N/A
- VYNE $493,000.00
- Revenue This Year
- CUBA N/A
- VYNE $32.31
- Revenue Next Year
- CUBA N/A
- VYNE N/A
- P/E Ratio
- CUBA N/A
- VYNE N/A
- Revenue Growth
- CUBA N/A
- VYNE 39.27
- 52 Week Low
- CUBA $2.25
- VYNE $1.57
- 52 Week High
- CUBA $4.14
- VYNE $4.09
- Technical
- Relative Strength Index (RSI)
- CUBA 51.00
- VYNE 59.02
- Support Level
- CUBA $2.42
- VYNE $2.65
- Resistance Level
- CUBA $2.55
- VYNE $3.05
- Average True Range (ATR)
- CUBA 0.06
- VYNE 0.23
- MACD
- CUBA -0.01
- VYNE -0.05
- Stochastic Oscillator
- CUBA 21.05
- VYNE 34.57
About CUBA Herzfeld Caribbean Basin Fund Inc. (The)
Herzfeld Caribbean Basin Fund Inc operates as a closed-end management investment company. The company's investment objective is to obtain long-term capital appreciation. The firm offers customized discretionary account management and fund management services to individual and institutional investors. The fund invests in equity and equity-linked securities of public and private companies, including United States-based companies, whose securities are traded principally on a stock exchange in a Caribbean Basin Country. The fund's revenue source is through the dividends it receives. Its investments are geographically allocated in the United States followed by Mexico, Puerto Rico, and other countries.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.